ArticleCerebellum (London, England)2019
Anti-GAD Antibodies and the Cerebellum: Where Do We Stand?
Article in Cerebellum (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Clinical Features of Glutamic Acid Decarboxylase-65 Neurological Autoimmunity: A Case Series From China.CNS neuroscience & therapeutics · 2025Article
- A candidate projective neuron type of the cerebellar cortex: the synarmotic neuron.European journal of histochemistry : EJH · 2024Review
- Advances in the Pathogenesis of Auto-antibody-Induced Cerebellar Synaptopathies.Cerebellum (London, England) · 2023Review
- GAD67-mediated GABA Synthesis and Signaling Impinges on Directing Basket Cell Axonal Projections Toward Purkinje Cells in the Cerebellum.Cerebellum (London, England) · 2022Article
- Autoantibodies directed against glutamate decarboxylase interfere with glucose-stimulated insulin secretion in dispersed rat islets.International journal of experimental pathology · 2022Article
- Acute Cerebellar Inflammation and Related Ataxia: Mechanisms and Pathophysiology.Brain sciences · 2022Review
- Dual ankyrinG and subpial autoantibodies in a man with well-controlled HIV infection with steroid-responsive meningoencephalitis: A case report.Frontiers in neurology · 2022Article
- A Guide for the Differential Diagnosis of Multiple System Atrophy in Clinical Practice.Journal of Parkinson's disease · 2022Review
- Anti-GAD associated post-infectious cerebellitis after COVID-19 infection.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- Antiglutamic Acid Decarboxylase 65 Antibody-Associated Hemiataxia.Neurology. Clinical practice · 2021Article
- Immune-Mediated Cerebellar Ataxias: Clinical Diagnosis and Treatment Based on Immunological and Physiological Mechanisms.Journal of movement disorders · 2021Article
- Fundamental Mechanisms of Autoantibody-Induced Impairments on Ion Channels and Synapses in Immune-Mediated Cerebellar Ataxias.International journal of molecular sciences · 2020Review
- GAD antibodies in neurological disorders - insights and challenges.Nature reviews. Neurology · 2020Review
- Neurological Syndromes Associated with Anti-GAD Antibodies.International journal of molecular sciences · 2020Review
- Recent Advances in the Treatment of Cerebellar Disorders.Brain sciences · 2019Review
- Article
- Cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-GAD65 antibodies (anti-GAD65 Abs) are associated with cerebellar ataxia (CA). The significance of anti-GAD65 Abs has been a focus of debates. Since GAD65 is intracellularly located and associated with type 1 diabetes mellitus and different clinical neurological phenotypes such as CA, stiff-person syndrome, and epilepsy, some researchers have argued that anti-GAD65 Abs have no pathogenic roles. On the other hand, recent physiological studies in vitro and in vivo have elucidated that binding of GAD65 by anti-GAD65 Abs elicits loss of GAD65 functions pertaining GABA release with an epitope dependence, leading to the development of CA. Internalization of autoantibodies has been also clarified. These studies provide substantial evidence of the pathogenesis of anti-GAD65 Abs in CA. We also discuss methodological problems in the identification of anti-GAD65 Abs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.